bifril comp 30 mg / 12.5 mg tabletti, kalvopäällysteinen
menarini international operations luxembourg s.a. - zofenoprilum calcicum,hydrochlorothiazidum - tabletti, kalvopäällysteinen - 30 mg / 12.5 mg - tsofenopriili ja diureetit
losartan medical valley 12.5 mg tabletti, kalvopäällysteinen
medical valley invest ab - losartan potassium - tabletti, kalvopäällysteinen - 12.5 mg - losartaani
losartan medical valley 50 mg tabletti, kalvopäällysteinen
medical valley invest ab - losartan potassium - tabletti, kalvopäällysteinen - 50 mg - losartaani
losartan medical valley 100 mg tabletti, kalvopäällysteinen
medical valley invest ab - losartan potassium - tabletti, kalvopäällysteinen - 100 mg - losartaani
valsartan sandoz 40 mg tabletti, kalvopäällysteinen
sandoz a/s sandoz a/s - valsartanum - tabletti, kalvopäällysteinen - 40 mg - valsartaani
valsartan sandoz 320 mg tabletti, kalvopäällysteinen
sandoz a/s sandoz a/s - valsartanum - tabletti, kalvopäällysteinen - 320 mg - valsartaani
valsartan krka 320 mg tabletti, kalvopäällysteinen
krka sverige ab - valsartan - tabletti, kalvopäällysteinen - 320 mg - valsartaani
verzenios
eli lilly nederland b.v. - abemaciclib - rintojen kasvaimet - antineoplastiset aineet - early breast cancerverzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative, node positive early breast cancer at high risk of recurrence (see section 5. in pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (lhrh) agonist. advanced or metastatic breast cancerverzenios is indicated for the treatment of women with hormone receptor (hr) positive, human epidermal growth factor receptor 2 (her2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. in pre- or perimenopausal women, the endocrine therapy should be combined with a lhrh agonist.
lorviqua
pfizer europe ma eeig - lorlatinib - karsinooma, ei-pienisoluinen keuhko - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
dexrapid vet. 2 mg/ml injektioneste, liuos
richter pharma ag - dexamethasone sodium phosphate - injektioneste, liuos - 2 mg/ml - deksametasoni